Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Teva “Authorized” Generic Agreement Approved By FTC

Executive Summary

The Federal Trade Commission is giving its formal blessing to an "authorized" generic agreement between Bristol-Myers Squibb and Teva involving the first generic version of Paraplatin (carboplatin)
Advertisement

Related Content

FTC Should Study Competitive Impact Of “Authorized” Generics, Senators Say
Paraplatin pediatric exclusivity ends
Mylan Takes “Authorized” Generics Fight To Congress, FTC, Courts
Medicaid “Best Price” May Be Avenue To Challenge “Authorized” Generics
Pfizer Accupril “Branded Generic” Plans Challenged By Teva
Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”
Paraplatin Settlement Lets Teva Distribute Generic Under Bristol License
Paraplatin Settlement Lets Teva Distribute Generic Under Bristol License
GPhA Wants “Authorized” Generics Stopped; Will FDA Help?
Bristol/FTC Settlement Brings PTO Standards Into Spotlight
Advertisement
UsernamePublicRestriction

Register

PS044060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel